107777-40-2

Upstream product

• 32884-23-4 2-benzyloxy-4-methoxybenzaldehyde 
• 13618-49-0 2-(benzyloxy)-4-methoxybenzoic acid 
• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 

Downstream Products

• 108975-76-4 4-<3-Chlor-2-hydroxy-propyloxy>-3-benzyloxy-anisol 
• 1374020-64-0 C₂₉H₂₆O₅ 
• 1374020-86-6 C₃₂H₃₂O₆ 
• 1374020-65-1 C₁₅H₁₄O₅ 
• 1374020-88-8 C₁₈H₂₀O₆ 

Relevant academic research and scientific papers

Psoromic acid is a selective and covalent rab-prenylation inhibitor targeting autoinhibited rabggtase

Post-translational attachment of geranylgeranyl isoprenoids to Rab GTPases, the key organizers of intracellular vesicular transport, is essential for their function. Rab geranylgeranyl transferase (RabGGTase) is responsible for prenylation of Rab proteins

Method of treatment for prostatic cancer

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.

Method of treatment for benign prostatic hyperplasia

Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an α1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

New catechol type non-steroidal drugs as 5-alpha reductase inhibitors

Described are new non-steroidal drugs for treatment of benign prostatic hyperplasia and other disorders mediated by high 5-alpha reductase activity, or high dihydrotestosterone levels, and other conditions of hyperandrogenic stimulation